Let’s partner to transform medicine—
and succeed together

At Assembly Bio, we take pride in the ingenuity, agility and rigor we apply to the scientific research we do. As a result, we’ve built some of the most cutting-edge drug discovery platforms in biopharma today. Our R&D effort is strong. But, it can be even stronger with the right academic and corporate partnerships in place.

Assembly Bio has an established R&D collaboration and licensing agreement with Allergan to jointly develop microbial biotherapeutic candidates for ulcerative colitis (ABI-M201), Crohn’s disease and inflammatory bowel syndromes.

If your organization is interested in collaborating with Assembly Bio
on a potential research and development venture in either of our HBV or microbial therapeutics programs, please contact us at: BD@assemblybio.com.